Ciltacabtagene autoleucel is a Legend Biotech Corp program in relapsed/refractory multiple myeloma (daratumumab-refractory subgroup). Its next catalyst is a Readout on Dec 12, 2026.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Relapsed/refractory multiple myeloma (daratumumab-refractory subgroup). Sponsor: Legend Biotech Corp (LEGN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for Ciltacabtagene autoleucel is a Readout on Dec 12, 2026.
No FDA decision for Ciltacabtagene autoleucel is in our archive yet.
In our records Ciltacabtagene autoleucel is under review or in development for Relapsed/refractory multiple myeloma (daratumumab-refractory subgroup).
Legend Biotech Corp (LEGN).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.